Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 9, No. 6, 606-616, November 2004; doi:10.1634/theoncologist.9-6-606
© 2004 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cianfrocca, M.
Right arrow Articles by Goldstein, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cianfrocca, M.
Right arrow Articles by Goldstein, L. J.

Prognostic and Predictive Factors in Early-Stage Breast Cancer

Mary Cianfrocca, Lori J. Goldstein

Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

Correspondence: Mary Cianfrocca, D.O., Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, Pennsylvania 19111, USA. Telephone: 215-728-2974; Fax: 215-728-3639; e-mail: M_Cianfrocca{at}fccc.edu

Breast cancer is the most common malignancy among American women. Due to increased screening, the majority of patients present with early-stage breast cancer. The Oxford Overview Analysis demonstrates that adjuvant hormonal therapy and polychemotherapy reduce the risk of recurrence and death from breast cancer. Adjuvant systemic therapy, however, has associated risks and it would be useful to be able to optimally select patients most likely to benefit. The purpose of adjuvant systemic therapy is to eradicate distant micrometastatic deposits. It is essential therefore to be able to estimate an individual patient’s risk of harboring clinically silent micrometastatic disease using established prognostic factors. It is also beneficial to be able to select the optimal adjuvant therapy for an individual patient based on established predictive factors. It is standard practice to administer systemic therapy to all patients with lymph node-positive disease. However, there are clearly differences among node-positive women that may warrant a more aggressive therapeutic approach. Furthermore, there are many node-negative women who would also benefit from adjuvant systemic therapy. Prognostic factors therefore must be differentiated from predictive factors. A prognostic factor is any measurement available at the time of surgery that correlates with disease-free or overall survival in the absence of systemic adjuvant therapy and, as a result, is able to correlate with the natural history of the disease. In contrast, a predictive factor is any measurement associated with response to a given therapy. Some factors, such as hormone receptors and HER2/neu overexpression, are both prognostic and predictive.

Key Words. Breast cancer • Prognostic factors • Predictive factors • Adjuvant therapy




This article has been cited by other articles:


Home page
Ann OncolHome page
W. Kwan, A. J. Al-Tourah, C. Speers, R. Woods, H. Kennecke, and I. A. Olivotto
Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1-2pN0 disease?
Ann. Onc., October 13, 2009; (2009) mdp396v1.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. L. Neal, J. Yao, W. Yang, X. Zhou, N. T. Nguyen, J. Lu, C. G. Danes, H. Guo, K.-H. Lan, J. Ensor, et al.
14-3-3{zeta} Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival
Cancer Res., April 15, 2009; 69(8): 3425 - 3432.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
H. Abe, R. A. Schmidt, K. Kulkarni, C. A. Sennett, J. S. Mueller, and G. M. Newstead
Axillary Lymph Nodes Suspicious for Breast Cancer Metastasis: Sampling with US-guided 14-Gauge Core-Needle Biopsy--Clinical Experience in 100 Patients1
Radiology, January 1, 2009; 250(1): 41 - 49.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
H. Abe, R. A. Schmidt, K. Kulkarni, C. A. Sennett, J. S. Mueller, and G. M. Newstead
Axillary Lymph Nodes Suspicious for Breast Cancer Metastasis: Sampling with US-guided 14-Gauge Core-Needle Biopsy--Clinical Experience in 100 Patients
Radiology, October 27, 2008; (2008) 2493071483.
[Abstract] [Full Text]


Home page
Am J Health Syst PharmHome page
L. B. Michaud
Treatment-experienced breast cancer
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S4 - S9.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
X.-J. Ma, R. Salunga, S. Dahiya, W. Wang, E. Carney, V. Durbecq, A. Harris, P. Goss, C. Sotiriou, M. Erlander, et al.
A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer
Clin. Cancer Res., May 1, 2008; 14(9): 2601 - 2608.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard
Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group
J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Dawood, K. Broglio, A. M. Gonzalez-Angulo, S.-W. Kau, R. Islam, G. N. Hortobagyi, and M. Cristofanilli
Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer
Clin. Cancer Res., March 15, 2008; 14(6): 1718 - 1725.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Dawood, K. Broglio, S.-W. Kau, R. Islam, W. F. Symmans, T. A. Buchholz, S. E. McGuire, F. Meric-Bernstam, M. Cristofanilli, G. N. Hortobagyi, et al.
Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response
Oncologist, January 1, 2008; 13(1): 6 - 15.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. G. Jakobsen, N. Rasmussen, A.-V. Laenkholm, and H. J. Ditzel
Phage Display Derived Human Monoclonal Antibodies Isolated by Binding to the Surface of Live Primary Breast Cancer Cells Recognize GRP78
Cancer Res., October 1, 2007; 67(19): 9507 - 9517.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. S. Bachmann, F. Otterbach, R. Callies, H. Nuckel, M. Bau, K. W. Schmid, W. Siffert, and R. Kimmig
The AA Genotype of the Regulatory BCL2 Promoter Polymorphism ( 938C>A) Is Associated with a Favorable Outcome in Lymph Node Negative Invasive Breast Cancer Patients
Clin. Cancer Res., October 1, 2007; 13(19): 5790 - 5797.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
H. Abe, R. A. Schmidt, C. A. Sennett, A. Shimauchi, and G. M. Newstead
US-guided Core Needle Biopsy of Axillary Lymph Nodes in Patients with Breast Cancer: Why and How to Do It
RadioGraphics, October 1, 2007; 27(suppl_1): S91 - S99.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
O. Tacca, F. Penault-Llorca, C. Abrial, M.-A. Mouret-Reynier, I. Raoelfils, X. Durando, J.-L. Achard, P. Gimbergues, H. Cure, and P. Chollet
Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Oncologist, June 1, 2007; 12(6): 636 - 643.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. T. Jorgensen, K. V. Nielsen, and B. Ejlertsen
Pharmacodiagnostics and Targeted Therapies--A Rational Approach for Individualizing Medical Anticancer Therapy in Breast Cancer
Oncologist, April 1, 2007; 12(4): 397 - 405.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
L Wang, L Peng, B Dong, L Kong, L Meng, L Yan, Y Xie, and C Shou
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome
Ann. Onc., October 1, 2006; 17(10): 1517 - 1522.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2004 by AlphaMed Press.
Advertisement